Cargando…
Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial
BACKGROUND: Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared rec...
Autores principales: | Corren, Jonathan, Saini, Sarbjit S, Gagnon, Remi, Moss, Mark H, Sussman, Gordon, Jacobs, Joshua, Laws, Elizabeth, Chung, Elinore S, Constant, Tatiana, Sun, Yiping, Maloney, Jennifer, Hamilton, Jennifer D, Ruddy, Marcella, Wang, Claire Q, O’Brien, Meagan P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379710/ https://www.ncbi.nlm.nih.gov/pubmed/34429614 http://dx.doi.org/10.2147/JAA.S318892 |
Ejemplares similares
-
Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis
por: Kamal, Mohamed A., et al.
Publicado: (2022) -
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020) -
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
por: Pavord, Ian D, et al.
Publicado: (2020) -
Subcutaneous Immunotherapy Improves the Symptomatology of Allergic Rhinitis
por: Lourenço, Edmir Américo, et al.
Publicado: (2015) -
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
por: Hamilton, Jennifer D., et al.
Publicado: (2021)